NIPD Pioneer Leverage Sequenom Laboratories' strong prenatal testing portfolio and CAP/CLIA credentials to cross-sell expanded genetic diagnostics to obstetricians, maternal-fetal medicine specialists, and genetics clinics seeking comprehensive fetal testing options.

Genome Expansion Position MaterniT Genome and NIPS capabilities as a broader screening solution to labs and clinics looking to augment their offerings beyond traditional targeted tests, highlighting the ability to screen all 23 chromosome pairs.

Brand Portfolio Promote the differentiated test brands such as MaterniT Genome, MaterniT21 PLUS, HerediT, SensiGene and VisibiliT to drive brand-based requests from referral networks and to establish preferred provider relationships.

Strategic Partnerships Identify potential collaborations with larger genomics and diagnostics players who acquired Sequenom’s portfolio or related capabilities, offering wholesale testing partnerships, technology licensing, or joint development opportunities.

Market Readiness Emphasize the company’s established CAP/CLIA accreditation, aging revenue profile, and proven deployment of molecular diagnostics to reassure mid-market labs and clinics seeking scalable, compliant prenatal testing capabilities.